These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22929880)

  • 1. Genomic Grade Index predicts postoperative clinical outcome of GIST.
    Bertucci F; Finetti P; Ostrowski J; Kim WK; Kim H; Pantaleo MA; Astolfi A; Polkowski M; Birnbaum D
    Br J Cancer; 2012 Oct; 107(8):1433-41. PubMed ID: 22929880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
    Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
    Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
    Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
    Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
    Rink L; Skorobogatko Y; Kossenkov AV; Belinsky MG; Pajak T; Heinrich MC; Blanke CD; von Mehren M; Ochs MF; Eisenberg B; Godwin AK
    Mol Cancer Ther; 2009 Aug; 8(8):2172-82. PubMed ID: 19671739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.
    Li Y; Meng X
    Ann R Coll Surg Engl; 2015 Apr; 97(3):215-20. PubMed ID: 26263807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GIST: adjuvant treatment in Austria].
    Brodowicz T; Kühr T
    Wien Med Wochenschr; 2009; 159(15-16):399-402. PubMed ID: 19696984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
    Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant treatment of GIST: patient selection and treatment strategies.
    Joensuu H
    Nat Rev Clin Oncol; 2012 Apr; 9(6):351-8. PubMed ID: 22525709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
    Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
    Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
    Cohen MH; Cortazar P; Justice R; Pazdur R
    Oncologist; 2010; 15(3):300-7. PubMed ID: 20200041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
    Gronchi A
    Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
    Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
    Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
    Joensuu H
    Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors.
    Perez D; Hauswirth F; Jäger D; Metzger U; Samartzis EP; Went P; Jungbluth A
    Int J Cancer; 2011 Jun; 128(12):2947-52. PubMed ID: 21140451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.